ERS Genomics licenses CRISPR gene editing tech to Otsuka

5-Mar-2021

Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan

ERS Genomics has announced the signing of a license agreement with Otsuka Pharmaceutical. The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

Eric Rhodes, CEO of ERS Genomics, said: “We are extremely pleased to be able to provide Otsuka with access to the CRISPR/Cas9 license. We hope this brings significant value to Otsuka as it applies the technology to its internal programs.”

Sign up for your free email newsletter

ERS Genomics licensed the technology to ZeClinics in February.

Companies